PATENT CLAIM ANALYSIS

Application Number: 15761725
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-12
Patent Classification: ["514", "017800"]

Abstract:
The present invention relates to an agent which inhibits Kallikrein-8 for use in the treatment or prevention of Alzheimer's disease and/or its precursor stages, as well as to methods, kits and uses relating thereto, including diagnostic tools.

Claim (Index 4):
An agent for use according to  claim 2 , which is capable of reducing the amount of Kallikrein-8 in the brain of a patient, wherein the agent is selected from a group consisting of a small molecule, a ribozyme, one or more nucleic acid(s), one or more oligonucleotide(s), a peptide and a protein, preferably wherein the agent is selected from (a) an agent which reduces the expression rate of Kallikrein-8, preferably wherein said agent knocks down the Kallikrein-8 expression, in particular wherein knocking down is reducing the transcription rate of the Kallikrein-8 gene, reducing the translation rate of the Kallikrein-8 messenger ribonucleic acid (mRNA), and/or reducing the transcript level of Kallikrein-8 and (b) a protein which is capable of proteolytic cleavage of Kallikrein-8.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 90.0
- Lexical Diversity: 1.10526
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12157664', '13393220', '14324289', '13701758', '11185907']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8017839771334404
- 35 USC 102 Novelty (BERT): 0.52487358892247
- Combined Prediction Score: 0.7740929383123434
- Mean Citation Score: 308.592442
- Max Citation Score: 328.3323
- Similarity Product: 202.97782773503064

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test